This story starts with a young graduate student in San Diego and leads all the way to Sierra Leone, to a unique hospital where Lassa fever victims arrive by the thousands every year.
Assistant Professor Seth Tomchik of the Florida campus of The Scripps Research Institute (TSRI) has received $2 million in funding from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS). The new five-year grant funding will support the study of neurofibromatosis type I, an inherited disorder that results from genetic mutations affecting a protein called neurofibromin (Nf1).
The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, today announced the appointment of Joel S. Marcus to its Board of Directors.
Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
With mosquito season looming in the Northern Hemisphere, doctors and researchers are poised to take on a new round of Zika virus infections. Now a new study by a large group of international researchers led by scientists at The Scripps Research Institute (TSRI) explains how Zika virus entered the United States via Florida in 2016—and how it might re-enter the country this year.
Clostridium botulinum is the bacterium that causes the neurointoxication, which produces one of the most potent toxins on earth and is classified as a potential bioterrorism threat. While no cure exists—and botulism treatment options are limited—a serendipitous discovery by scientists at The Scripps Research Institute (TSRI) may provide a new therapy that can stop the neurotoxin even in its more severe, advanced stages of action.
In their quest to replicate themselves, viruses have gotten awfully good at tricking human cells into pumping out viral proteins. That’s why scientists have been working to use viruses as forces for good: to deliver useful genes to human cells and help patients who lack important proteins or enzymes.
A team of researchers led by Associate Professor Vijay Reddy at The Scripps Research Institute (TSRI) has now uncovered the structural details that make one virus a better tool for future therapies than its closely related “cousin.”
Three chemists from The Scripps Research Institute (TSRI)—Dale Boger, Jin-Quan Yu and Phil Baran—have received awards from the Royal Society of Chemistry (RSC), a renowned professional organization for chemists based in the United Kingdom, with more than 54,000 members worldwide.
Despite intense research, there’s been much confusion regarding the exact role of a protein in a critical cancer-linked pathway. On one hand, the protein is described as a cell proliferation inhibitor, on the other, a cell proliferation activator, a duality that has caused a great deal of scientific head scratching. Now scientists from the Florida campus of The Scripps Research Institute (TSRI) have solved the conundrum, uncovering the regulatory machinery underlying the function of a protein, called angiomotin.
Scientists at The Scripps Research Institute (TSRI) in La Jolla have revealed new clues to the wiring of the brain. A team led by Associate Professor Anton Maximov found that neurons in brain regions that store memory can form networks in the absence of synaptic activity.
Chemists at The Scripps Research Institute (TSRI) have discovered a new method that greatly simplifies, and in many cases enables for the first time, the making of a vast range of organic molecules.
Chemists at The Scripps Research Institute (TSRI) have developed a broad and strikingly easy method for synthesizing a class of molecules that have demonstrated value as pharmaceuticals.
A new study led by scientists at The Scripps Research Institute (TSRI) could help researchers develop personalized treatments for alcoholism and alcohol use disorder.
Professor Michael Farzan, co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute (TSRI) has received $4.8 million in funding through a 2017 Avant-Garde Award for HIV/AIDS research from the National Institutes of Health’s National Institute on Drug Abuse (NIDA). The new funding will support a five-year project, led by Farzan, to bring a potential HIV vaccine closer to human clinical trials.
Scientists at The Scripps Research Institute (TSRI) have found a way to tether HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus.
The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, today announced the appointment of Ronald W. Burkle to its Board of Directors—adding another world-renowned business leader and philanthropist to its newly restructured board.
New research from The Scripps Research Institute (TSRI) suggests that the reason methamphetamine users find it so hard to quit—88 percent of them relapse, even after rehab—is that meth takes advantage of the brain’s natural learning process.
Scientists at The Scripps Research Institute (TSRI) have developed a method to analyze the glycan shield on HIV’s protective outer glycoprotein, developed as a potential HIV vaccine candidate.
A team of scientists from the Florida campus of The Scripps Research Institute (TSRI), Dana-Farber Cancer Institute, Harvard Medical School and the Yale University School of Medicine, among others, have identified a new class of compounds that reduce production of glucose in the liver.
Scientists from the Florida campus of The Scripps Research Institute (TSRI), the University of California (UC), San Diego and the University of Illinois have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors.
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.
The MagnaSafe Registry, a new multicenter study led by scientists at The Scripps Research Institute (TSRI), has demonstrated that appropriately screened and monitored patients with standard or non-MRI-conditional pacemakers and defibrillators can undergo MRI at a field strength of 1.5 tesla without harm.
Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.
In a study recently published online in the journal Molecular Metabolism, Chakraborty and his colleagues have shown that deleting the gene for this protein, known as IP6K1, protects animal models from both obesity and diabetes.
A pair of scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health (NIH) to create the next generation of breast cancer treatments for the thousands of patients whose current treatment options are limited.
In a new study, researchers at The Scripps Research Institute (TSRI) have described how two important molecules in the brain work together to trigger intense anxiety.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered the details behind the virus’s unique ability to cross the placental barrier and expose the fetus to a range of birth defects that often go beyond microcephaly to include eye and joint injury, and even other types of brain damage.
Scientists at The Scripps Research Institute (TSRI) have found that deep brain stimulation (DBS) can greatly reduce the compulsion to use heroin in standard rat models of addiction.
A new study led by scientists at The Scripps Research Institute (TSRI) is giving researchers a first look at the early stages of brain development in patients with Fragile X syndrome, a disorder that causes mild to severe intellectual disability and is the most common genetic cause of autism spectrum disorder.
Biologists at The Scripps Research Institute (TSRI) have identified a brain hormone that appears to trigger fat burning in the gut. Their findings in animal models could have implications for future pharmaceutical development.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.8 million from the National Institute of General Medical Sciences of the National Institutes of Health to develop a series of drug candidates for a number of diseases, including heart disease, rheumatoid arthritis and several neurodegenerative disorders.
A team led by scientists at The Scripps Research Institute (TSRI) has developed a versatile new method that should enhance the discovery of new drugs and the study of proteins.
The Scripps Research Institute (TSRI), a leading non-profit biomedical research institute, today announced a research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to pioneer new DNA-encoded library (DEL) technology, including new synthetic chemistry for the creation of next-generation DELs, a potentially transformative technology for early stage drug discovery research.
Biologists on the Florida campus of The Scripps Research Institute (TSRI) have discovered a new mechanism that likely underlies how we feel force or touch.
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed a new tool for studying the molecular details of protein structure.